Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | RECQL | P46063 | 1/20 | 0.37 |
| ▸ | CA12 | O43570 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | CA7 | P43166 | 1/20 | 0.36 |
| ▸ | CA9 | Q16790 | 1/20 | 0.36 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2292877 | 1.00 | HCAR2 (0.44) | HCAR2L3MBTL1TDP1TSHRMAPT | |
| SCHEMBL101275 | 0.90 | HCAR2 (0.42) | HCAR2L3MBTL1TDP1TSHRMAPT | |
| SCHEMBL7512242 | 0.87 | HCAR2 (0.52) | HCAR2L3MBTL1TDP1MAPTCA12 | |
| SCHEMBL7512241 | 0.87 | HCAR2 (0.52) | HCAR2L3MBTL1TDP1MAPTCA12 | |
| SCHEMBL18828565 | 0.87 | HCAR2 (0.52) | HCAR2L3MBTL1TDP1MAPTCA12 | |
| SCHEMBL9585475 | 0.87 | HCAR2 (0.47) | HCAR2L3MBTL1TDP1TSHRMAPT | |
| SCHEMBL9585569 | 0.84 | ATM (0.56) | HCAR2TSHRMAPTALDH1A1NPSR1 | |
| SCHEMBL425748 | 0.84 | HCAR2 (0.48) | HCAR2L3MBTL1TDP1MAPTCA12 | |
| SCHEMBL1126533 | 0.84 | HCAR2 (0.48) | HCAR2L3MBTL1TDP1MAPTCA12 | |
| SCHEMBL1126534 | 0.84 | HCAR2 (0.48) | HCAR2L3MBTL1TDP1MAPTCA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3116873-B1 | HEXAHYDRODIAZEPINOQUINOLINES CARRYING A CYCLIC RADICAL | ABBVIE DEUTSCHLAND (DE) | 2018-02-28 | — | — | EP | disclosed |
| US-20170158693-A1 | HEXAHYDRODIAZEPINOQUINOLINES CARRYING A CYCLIC RADICAL | ABBVIE DEUTSCHLAND (DE) | 2017-06-08 | — | — | US | disclosed |
| US-9573950-B2 | Substituted [1,4]diazepino[6,7,1-ij]quinolines as serotonin 5-HT2C receptor modulators | ABBVIE DEUTSCHLAND GMBH & CO KG (DE) | 2017-02-21 | — | — | US | disclosed |
| EP-3116873-A1 | HEXAHYDRODIAZEPINOQUINOLINES CARRYING A CYCLIC RADICAL | AbbVie Deutschland GmbH & Co. KG (DE) | 2017-01-18 | — | — | EP | disclosed |
| US-20150259343-A1 | HEXAHYDRODIAZEPINOQUINOLINES CARRYING A CYCLIC RADICAL | AbbVie Deutschland GmbH & Co. KG (DE) | 2015-09-17 | — | — | US | disclosed |
| WO-2015136090-A1 | HEXAHYDRODIAZEPINOQUINOLINES CARRYING A CYCLIC RADICAL | AbbVie Deutschland GmbH & Co. KG (DE) | 2015-09-17 | — | — | WO | disclosed |
| EP-2266983-B1 | NITROGENATED 5-MEMBERED HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL (JP) | 2013-06-05 | — | — | EP | disclosed |
| US-8349886-B2 | Nitrogenated 5-membered heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-01-08 | — | — | US | disclosed |
| US-20110190335-A1 | NITROGENATED 5-MEMBERED HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-08-04 | — | — | US | disclosed |
| EP-2266983-A1 | NITROGENATED 5-MEMBERED HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2010-12-29 | — | — | EP | disclosed |
| EP-0406839-B1 | Process for the preparation of 1-(4-tetrahydropyranyl) or 1-(4-tetrahydrothiopyranyl)-prop-1-en-3-ones | BASF AG (DE) | 1995-02-01 | — | — | EP | disclosed |
| US-5221753-A | PREPARATION OF 1-(4-TETRAHYDROPYRANYL)- OR 1-(4-TETRAHYDROTHIOPYRANYL)PROP-1-EN-3-ONES | BASF AKTIENGESELLSCHAFT (DE) | 1993-06-22 | — | — | US | disclosed |
| US-4739066-A | HYPOTENSIVE AGENTS, ANGIOTENSIN INHIBITORS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1988-04-19 | — | — | US | disclosed |
| US-4638000-A | HYPOTENSIVES, ANGIOTENSIN INHIBITORS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1987-01-20 | — | — | US | disclosed |
| US-4591458-A | ENZYME INHIBITORS; HYPOTENSIVE AGENTS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1986-05-27 | — | — | US | disclosed |
| US-4548932-A | ANGIOTENSIN INHIBITOR, HYPOTENSIVE AGENT | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1985-10-22 | — | — | US | disclosed |
| EP-0156455-A2 | Condensed seven-membered ring compounds, their production and use | Takeda Chemical Industries, Ltd. (JP) | 1985-10-02 | — | — | EP | disclosed |
| EP-0135349-A1 | Condensed seven-membered ring compounds and their production and use | Takeda Chemical Industries, Ltd. (JP) | 1985-03-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170158693-A1 | HEXAHYDRODIAZEPINOQUINOLINES CARRYING A CYCLIC RADICAL | HTR2C, HTR2A, HTR5A | HCAR2 42/4885L3MBTL1 4882/4885TDP1 2265/4885 |
| US-20150259343-A1 | HEXAHYDRODIAZEPINOQUINOLINES CARRYING A CYCLIC RADICAL | HTR2C, HTR2A, HTR5A | HCAR2 42/4885L3MBTL1 4882/4885TDP1 2265/4885 |
| US-20110190335-A1 | NITROGENATED 5-MEMBERED HETEROCYCLIC COMPOUND | GCKR, GCK, SLC5A1 | HCAR2 2829/4885L3MBTL1 3925/4885TDP1 4142/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.